Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (?75) patients

Basit Öğe Kaydı
dc.authoridAkin Telli, Tugba/0000-0001-6535-6030
dc.authoridGürbüz, Mustafa/0000-0001-7680-4142
dc.authoridGüç, Zeynep Gülsüm/0000-0001-8960-2208
dc.authoridTürkkan, Görkem/0000-0002-9084-2599
dc.authoridErturk, Ismail/0000-0001-6835-0988
dc.authoridYaşar, Hatime Arzu/0000-0002-0545-1383
dc.authoridÖksüzoğlu Çakmak, Ömür Berna/0000-0002-2756-8646
dc.authorwosidDOGAN, MUTLU/GNP-7311-2022
dc.authorwosidAkin Telli, Tugba/GSE-4006-2022
dc.authorwosidArslan, Cagatay/I-1932-2016
dc.authorwosidGürbüz, Mustafa/CAJ-3354-2022
dc.authorwosidGüç, Zeynep Gülsüm/AGX-1276-2022
dc.authorwosidKaraoglu, Aziz/HKM-3509-2023
dc.authorwosidTürkkan, Görkem/E-7048-2017
dc.contributor.authorAlkan, Ali
dc.contributor.authorGuc, Zeynep Gulsum
dc.contributor.authorGurbuz, Mustafa
dc.contributor.authorozgun, Guliz
dc.contributor.authorDegirmencioglu, Serkan
dc.contributor.authorDogan, Mutlu
dc.contributor.authorTelli, Tugba Akin
dc.date.accessioned2024-06-12T11:08:25Z
dc.date.available2024-06-12T11:08:25Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric patients. We aimed to evaluate the efficacy of Enzalutamide (ENZA) and Abiraterone Acetate (AA) as a first-line treatment of mCRPC in elderly patients. Materials and methods: The geriatric patients (>= 75 years of age) with a diagnosis of mCRPC and treated with first-line ENZA or AA were included. The impacts of clinical parameters and treatment modalities on overall survival (mOS) were analyzed retrospectively and Cox regression analysis was performed. Results: One hundred thirty-four mCRPC patients (77 in AA, 57 in ENZA), with a median age of 81 (75-93) were analyzed. The patient and disease characteristics were similar between arms. While there were more grade 1-2 toxicities in AA arm (45.5% vs 17.5%, P = 0.001), the discontinuation due to toxicity was similar between groups (8.5% vs 5.9%, P = 0.81). The mOS was 18.0 months (95% CI, 15.2-20.7) in AA, and 20.0 months (95% CI, 4.4-35.5) in ENZA arm (P = 0.47). In multivariate analysis, high Gleason score (>= 8) (HR: 2.0 (95% CI, 1.1-3.4), P = 0.009) and high initial PSA values (>= 100 ng/mL) (HR: 2.6 (95% CI, 1.5-4.8), P = 0.001) were poor prognostic factors. The choice of AA vs ENZA was insignificant as a predictor of OS (HR: 0.87 (95% CI, 0.48-1.56), P = 0.65). Conclusion: In the first-line treatment of mCRPC in elderly (>= 75) patients, AA and ENZA showed similar results in terms of mPFS and mOS. The clinical impacts of second-generation androgen receptor pathway inhibitors in the elderly population should be tested in prospective randomized studies.en_US
dc.identifier.doi10.31083/jomh.2021.041
dc.identifier.endpage134en_US
dc.identifier.issn1875-6867
dc.identifier.issn1875-6859
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85116774416en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage128en_US
dc.identifier.urihttps://doi.org/10.31083/jomh.2021.041
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22422
dc.identifier.volume17en_US
dc.identifier.wosWOS:000699924300001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherMre Pressen_US
dc.relation.ispartofJournal Of Mens Healthen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectMetastatic Castration-Resistant Prostate Canceren_US
dc.subjectEnzalutamideen_US
dc.subjectAbiraterone Acetateen_US
dc.subjectElderlyen_US
dc.subjectChemotherapyen_US
dc.subjectDocetaxelen_US
dc.subjectSurvivalen_US
dc.subjectOutcomesen_US
dc.subjectSafetyen_US
dc.subjectMenen_US
dc.titleEnzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (?75) patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu